Drug Insight: vitamin D analogs in the treatment of secondary hyperparathyroidism in patients with chronic kidney disease

This publication has 69 references indexed in Scilit:

• Inhibition of Parathyroid Hormone: A Dose Equivalency Study of Paricalcitol and Doxercalciferol
  American Journal of Nephrology, 2005
• Comparison of the efficacy of an oral calcitriol pulse or intravenous 22-oxacalcitriol therapies in chronic hemodialysis patients
  Clinical and Experimental Nephrology, 2005
• Pretreatment plasma intact parathyroid hormone and serum calcium levels, but not serum phosphate levels, predict the response to maxacalcitol therapy in dialysis patients with secondary hyperparathyroidism
  Clinical and Experimental Nephrology, 2005
• Paricalcitol-treated patients experience improved hospitalization outcomes compared with calcitriol-treated patients in real-world clinical settings
  Nephrology Dialysis Transplantation, 2004
• Effective suppression of parathyroid hormone by 1α-hydroxy-vitamin D2 in hemodialysis patients with moderate to severe secondary hyperparathyroidism
  Kidney International, 1997
• A deficit of calcitriol synthesis may not be the initial factor in the pathogenesis of secondary hyperparathyroidism
  Nephrology Dialysis Transplantation, 1996
• Effect of 22-oxacalcitriol on hyperparathyroidism of dialysis patients: results of a preliminary study
  Nephrology Dialysis Transplantation, 1996
• 1,25(OH)2D3 administration in moderate renal failure: A prospective double-blind trial
  Kidney International, 1989
• Synthetic studies of vitamin D3 analogues. VIII Synthesis of 22-oxavitamin D3 analogues.
  CHEMICAL & PHARMACEUTICAL BULLETIN, 1986
• Studies on the mechanism of action of calciferol VII. Localization of 1,25-dihydroxy-vitamin D3 in chick parathyroid glands
  Biochemical and Biophysical Research Communications, 1975